IM Therapeutics is developing immunotherapeutic drugs for autoimmune diseases. Autoimmune diseases affect about 4% of the world’s population manifested through 80 different disease conditions. Gene variants of HLA protein are common mutations associated with the disease. Using their technology platform, IMT is screening millions of drug-like molecules using computational algorithms and 3D models to see if they can target specific HLA proteins, preventing an autoimmune response. Currently, IMT is prioritizing therapies for Type 1 Diabetes and Celiac Disease.

IM Therapeutics

Founded: 2015
Location: Woburn, MA
Employee range: 1 - 10
Clinical stage: Clin1b
Therapy area: Diabetes (1)
Drug types: END, GI, IMM
Lead product: IMT-002
Funding: $10M A Oct 2019

Drug notes:

About:

Jobs: